Taladegib is under clinical development by Endeavor BioMedicines and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Taladegib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Taladegib (LY-2940680) is under development for the treatment of idiopathic pulmonary fibrosis (IPF) and advanced solid tumors harboring PTCH1 loss of function mutations. The drug candidate targets smoothened (SMO) receptor. The drug candidate is administered through oral route. It was also under development for advanced cancers including epithelial ovarian, fallopian tube or primary peritoneal cancer and adenocarcinoma of the esophagus or gastroesophageal junction, small cell lung cancer, recurrent or refractory rhabdomyosarcoma, refractory medulloblastoma and as a topical formulation for superficial and nodular basal cell carcinoma.
Endeavor BioMedicines overview
Endeavor BioMedicines (Endeavor) is a clinical-stage company developing a best-in-class Hedgehog inhibitor for idiopathic pulmonary fibrosis. It designs and develops hedgehog inhibitors for the treatment of idiopathic pulmonary fibrosis (IPF). The company is investigating ENV-101, a small-molecule inhibitor to treat basal cell carcinoma and acute myelogenous leukemia by targeting and activating the hedgehog signaling pathway during embryonic development. It also investigates ENV-501, an antibody-drug conjugate.
For a complete picture of Taladegib’s drug-specific PTSR and LoA scores, buy the report here.